XML 78 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Employee Benefit Plans and Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Treasury Share Activity Table Text Block
The following table summarizes our treasury share activity for the periods shown. No treasury share activity occurred during the twelve months ended December 31, 2020.
Twelve Months Ended
December 31,
(In millions)20222021
Shares issued in connection with 2023 Notes conversions0.4 0.8 
Shares received from Note Hedge(0.3)(1.0)
Shares issued in connection with the Restated Collaboration Agreement2.9 — 
Shares repurchased under the Share Repurchase Program(6.6)— 
Schedule of RSU and PSU Activity
A summary of RSU and PSU activity under the 2015 Plan for the twelve months ended December 31, 2022, 2021 and 2020 is as follows:
Nonvested RSU and PSU Activity
(In millions, except weighted average grant date fair value)Shares Available for GrantSharesWeighted 
Average
Grant Date
Fair Value
Aggregate
Intrinsic Value
Balance at December 31, 201919.6 7.2 $24.20 
Granted(2.0)2.0 75.09 
Vested— (4.1)23.10 
Forfeited0.4 (0.4)34.36 
Balance at December 31, 202018.0 4.7 45.88 $430.6 
Granted(1.7)1.7 87.67 
Vested— (2.9)34.47 
Forfeited0.5 (0.5)69.77 
Balance at December 31, 202116.8 3.0 76.88 403.8 
Granted(1.9)1.9 96.79 
Vested— (1.6)63.90 
Forfeited0.4 (0.4)92.54 
Balance at December 31, 202215.3 2.9 $94.08 $325.6 
Schedule of Share-Based Compensation Expenses The following table summarizes the share-based compensation expense included in our consolidated statements of operations for the periods shown.
Twelve Months Ended
December 31,
(In millions)202220212020
Cost of sales$11.1 $8.5 $14.6 
Research and development42.7 41.0 37.8 
Selling, general and administrative72.7 63.9 67.0 
Total share-based compensation expense$126.5 $113.4 $119.4 
Schedule of Valuation Assumptions for Employee Stock Purchase Plan We estimate the fair value of ESPP purchase rights on the date of grant using the Black-Scholes option pricing model and the assumptions below for the specified reporting periods.
Twelve Months Ended
December 31,
202220212020
Risk free interest rate
0.60% - 3.34%
0.06% - 0.07%
0.13% - 0.95%
Dividend yield— %— %— %
Expected volatility of Dexcom common stock
45% - 55%
36% - 45%
51% - 63%
Expected life (in years)0.50.50.5